174891-10-2

Basic information

• Product Name: (5-AMINO-2H-PYRAZOL-3-YL)-ACETIC ACID
• Synonyms: (5-AMINO-2H-PYRAZOL-3-YL)-ACETIC ACID;5-Amino-1H-pyrazole-3-aceticacid;2-(3-amino-1H-pyrazol-5-yl)acetic acid;2-(5-aMino-1H-pyrazol-3-yl)acetic acid;(5-Aminopyrazol-3-yl)acetic acid;5-Amino-1H-pyrazol-3-ylacetic acid;EOS-61782
• CAS NO: 174891-10-2
• Molecular Formula: C₅H₇N₃O₂
• Molecular Weight: 141.13
• EINECS: 1312995-182-4
• Mol File: 174891-10-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 504.4 °C at 760 mmHg
• Flash Point: 258.8 °C
• Appearance: /
• Density: 1.555
• Vapor Pressure: 5.4E-11mmHg at 25°C
• Refractive Index: 1.676
• Storage Temp.: 2-8°C(protect from light)
• PKA: 3.54±0.10(Predicted)
• CAS DataBase Reference: (5-AMINO-2H-PYRAZOL-3-YL)-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (5-AMINO-2H-PYRAZOL-3-YL)-ACETIC ACID(174891-10-2)
• EPA Substance Registry System: (5-AMINO-2H-PYRAZOL-3-YL)-ACETIC ACID(174891-10-2)

Safety Data

• Hazardous Substances Data: 174891-10-2(Hazardous Substances Data)

Usage

General Description

(5-Amino-2H-pyrazol-3-yl)-acetic acid is a chemical compound with the molecular formula C6H7N3O2. It is also known as 5-amino-3H-pyrazol-3-yl acetic acid. (5-AMINO-2H-PYRAZOL-3-YL)-ACETIC ACID is a pyrazole derivative and contains both an amino group and a carboxylic acid group. It is used in organic synthesis as a building block for the preparation of various pharmaceuticals, agrochemicals, and other bioactive compounds. Its structure and properties make it a versatile intermediate in the production of a variety of chemical products.

InChI:InChI=1/C5H7N3O2/c6-4-1-3(7-8-4)2-5(9)10/h1H,2H2,(H,9,10)(H3,6,7,8)

Upstream product

• 54711-21-6 5-amino-3-(cyanomethyl)-1H-pyrazole-4-carbonitrile 
• 54711-21-6 3-amino-5-(cyanomethyl)-1H-pyrazole-4-carbonitrile 

Downstream Products

• 557770-91-9 2-(3-((7-(3-chloropropoxy)quinazolin-4-yl)amino)-1H-pyrazol-5-yl)acetic acid 
• 1258412-00-8 C₁₄H₁₂ClF₃N₄O₂ 
• 1186390-25-9 sodium methyl 4-(4-(5-(2-(3-fluorophenylamino)-2-oxoethyl)-1H-pyrazol-3-ylamino)quinazolin-7-yl)benzoate 
• 1186390-31-7 2-(4-(4-(4-(5-(2-(3-fluorophenylamino)-2-oxoethyl)-1H-pyrazol-3-ylamino)quinazolin-7-yl)benzoyl)piperazin-1-yl)ethyl dihydrogen phosphate 
• 1186390-17-9 C₃₈H₄₅FN₈O₃Si 
• 1186390-26-0 2-(3-(7-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinazolin-4-ylamino)-1H-pyrazol-5-yl)-N-(3-fluorophenyl)acetamide 
• 1186390-09-9 N-(3-fluorophenyl)-2-(3-(7-(4-(4-(2-hydroxyethyl)piperazine-1-carbonyl)phenyl)quinazolin-4-ylamino)-1H-pyrazol-5-yl)acetamide 
• 1186390-07-7 (S)-N-(3-fluorophenyl)-2-(3-(7-(4-(3-fluoropyrrolidin-1-ylsulfonyl)phenyl)quinazolin-4-ylamino)-1H-pyrazol-5-yl)acetamide 
• 1186390-24-8 methyl 4-(4-(5-(2-(3-fluorophenylamino)-2-oxoethyl)-1H-pyrazol-3-ylamino)quinazolin-7-yl)benzoate 
• 1186390-23-7 N-(3-fluorophenyl)-2-(3-(quinazolin-4-ylamino)-1H-pyrazol-5-yl)acetamide 
• 722544-85-6 2,2,2-trifluoro-N-(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)acetamide 
• 1258412-04-2 C₁₄H₁₂F₄N₄O₂ 
• 957881-03-7 2-{ethyl[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)proplyl]amino}ethyl dihydrogen phosphate 
• 722544-50-5 di-tert-butyl 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl phosphate 

Relevant articles and documents

Novel quinazoline-containing compound, and intermediate and application thereof

The present invention discloses a quinazoline-containing compound having the formula (IA), (IB) or (IC), or a pharmaceutically acceptable salt or a prodrug molecule thereof. The compound is suitable for use as an Aurora kinase inhibitor and is thus suitable for the treatment of Aurora-mediated diseases characterized by excessive or abnormal cell proliferation, for example, cancer.

TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS

The present invention comprises inter alia compounds as shown in formula (I) or a pharmaceutically acceptable salt thereof.

Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase

The Aurora kinases have been the subject of considerable interest as targets for the development of new anticancer agents. While evidence suggests inhibition of Aurora B kinase gives rise to the more pronounced antiproliferative phenotype, the most clinically advanced agents reported to date typically inhibit both Aurora A and B. We have discovered a series of pyrazoloquinazolines, some of which show greater than 1000-fold selectivity for Aurora B over Aurora A kinase activity, in recombinant enzyme assays. These compounds have been designed for parenteral administration and achieve high levels of solubility by virtue of their ability to be delivered as readily activated phosphate derivatives. The prodrugs are comprehensively converted to the des-phosphate form in vivo, and the active species have advantageous pharmacokinetic properties and safety pharmacology profiles. The compounds display striking in vivo activity, and compound 5 (AZD1152) has been selected for clinical evaluation and is currently in phase 1 clinical trials.